Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: Turner syndrome. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Recommendation - Pharmacoeconomic Report. 2014 Authors' conclusions Based on CDR calculations using a confidential price of $vvvvvv per mg, the daily cost of the maximum dose of Genotropin ($vvvvvv; 0.33 mg/kg/week) is less than that of Humatrope ($100; 0.375 mg/kg/week), Nutropin ($84; 0.375 mg/kg/week), and Saizen ($96; 0.320 to 0.375 mg/kg/week). Indexing Status Subject indexing assigned by CRD MeSH Cost-Benefit Analysis; Humans; Turner Syndrome Growth Hormone Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000804 Date abstract record published 17/07/2014 |